Global At-home Self Testing Kits Market Report 2022 to 2035: by Type of Test Format, Type of Biofluid, Analyzed Therapeutic Area and Key Geographical Regions – ResearchAndMarkets.com

Global At-home Self Testing Kits Market Report 2022 to 2035: by Type of Test Format, Type of Biofluid, Analyzed Therapeutic Area and Key Geographical Regions - ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “At-home Self Testing Kits Market Distribution by Type of Test Format, Type of Biofluid Analyzed Therapeutic Area and Key Geographical Regions, Europe, Asia-Pacific, Africa and South America): Industry Trends and Global Forecasts, 2022-2035” report has been added to ResearchAndMarkets.com’s offering.

This report features an extensive study of the current market landscape and future potential associated with the at-home self-testing kits market. The study also includes an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.

Since the approval of the first over-the-counter test kits in the early 1976, there has been a substantial increase in the development initiatives focused on such products. In this context, it is worth highlighting that over 20 million at-home pregnancy test kits are being annually sold in the US.

Companies have also developed at-home diagnostic kits for the detection and diagnosis of various diseases, such as human immunodeficiency virus (HIV) infection, diabetes, Hepatitis C, colon cancer and COVID-19. Specifically, post the onset of COVID-19, there has been an upsurge in the demand for self-testing kits.

In fact, in 2021, more than 100 at-home self-testing kits were approved by the USFDA for the diagnosis of COVID-19. The popularity of these kits can be attributed to the fact that they are more reliable, efficient, high yielding, as well as compatible with a broad range of input samples, including blood, cells, tissues, plasma, saliva and microbes.

Given the extensive utilization of at-home testing kits in the diagnosis of a myriad of disease indications, there has been a significant rise in investments in this domain. Over USD 2.2 billion has been invested in this domain by various government institutions in the US, over the last five years.

Further, the current market landscape is consolidated and primarily dominated by the kits being developed to detect pregnancies, monitoring glucose and ovulation patterns. We believe that, with an increase in the number of point-of-care test kits being developed across various therapeutic areas, such as infectious diseases and celiac diseases, and their subsequent commercialization, the opportunities for self-testing kit developers is likely to increase in the foreseen future.

At present, efforts are also ongoing to connect at-home diagnostic tests with telemedicine; this is expected to enable a rapid turnaround time. The ongoing innovations in this market are anticipated to bring a positive revolution in the healthcare domain. Given the continuous efforts being undertaken by industry players, the at-home self-testing kits market is poised to witness healthy growth over the next decade.

One of the key objectives of the report was to estimate the current opportunity and future size of at-home self-testing kits market. We have provided informed estimates on the likely evolution of the market in the short to mid-term and long term, over the period 2022-2035.

Companies Mentioned

Abbott Diabetes Care (A Subsidiary of Abbott)

ACON Laboratories

AdvaCare Pharma

Agera Health

Alfa Scientific Designs

Ameritek

ApexBio

Arizona State University

ARKRAY

Artron Laboratories

Ascensia Diabetes Care

Atomo Diagnostics

Auburn University

Bionime

Biosynex

Biotron Diagnostics

Boston University Medical Campus

Brigham Young University

Brown University

Calpro (Acquired by Svar Life Sciences)

Carnegie Mellon University

Case Western Reserve University

CEI Technology

Central Michigan University

Chembio Diagnostics

Clarity Diagnostics

Cnoga Medical

Colorado State University

Columbia University Health Sciences

CommonSense (Acquired by Peptonic Medical)

Confirm Biosciences

Cornell University

Delfran Pharmaceuticals

DNX Medical

Drexel University

Duke University

e-LinkCare Meditech

Emory University

EPS biotechnology

Florida International University

ForaCare

GE Healthcare

Genlantis Diagnostics

Georgetown University

Georgia State University

Germaine Laboratories

GlucoMe

iHealth Labs

i-SENS

Johns Hopkins University

Johnson & Johnson

And Many More Companies!

Key Questions Answered

Who are the leading players engaged in the manufacturing of at-home self-testing kits?

What is the most common diagnostic assay offered by at-home self-testing kit manufacturers?

What are the key regulatory frameworks for at-home self-testing kits across different geographical regions?

Which companies / institutes have received grants for the research and development of at-home self-testing kits?

What are the key factors influencing the price of at-home self-testing kits?

What is the likely valuation / net worth of companies engaged in this domain?

What is the current, global demand for at-home self-test kits?

How is the current and future market opportunity likely to be distributed across key market segments?

What is the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments?

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET OVERVIEW

5. GRANTS ANALYSIS

6. COMPANY COMPETITIVENESS ANALYSIS

7. COMPANY PROFILES

8. BOWMAN CLOCK PRICING STRATEGY

9. COMPANY COMPARABLE ANALYSIS

10. DEMAND ANALYSIS

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS

12. ATTRACTIVENESS COMPETITIVENESS MATRIX

13. CONCLUDING REMARKS

14. INTERVIEW TRANSCRIPTS

15. APPENDIX I: TABULATED DATA

16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/2wly2m.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.